That's a good find.A bacterial PPV of 58% is a bit worrying, but...

That's a good find.

A bacterial PPV of 58% is a bit worrying, but the NPV is 100% so as it's a yes / no test, I guess that really doesn't matter too much.


I'm still struggling to see the value of distributing another companies product (Binx deal) and then turning around and saying 'yeah our test is better'

If I'd just spent $$$ on a binx system via Lumos, and then get told it's inferior, I'd probably not be too happy.


I'm sure there is a big part that's not been announced, or I'm a bit slow and just not getting it!


Bottom line is - this is a 12 - 18 months wait until the new contracts kick in to provide 'royalties' every year.

In the interim, we are 100% reliant on FebriDx to push the company forward.

As foe ViriDx - sell as much existing stock as we can, even if we slash 90% off the price, as it's going to be discontinued next year.

We've already made a stockpile so better to get something for it, rather than nothing.


Any unsold stock can always be donated to a charity for a tax write-off I guess.

I'll be adding more shares as I can to my small pile, as I don't see too much SP action in the next year (maybe rise to 10 - 12c), unless FebriDx sells in vast quantities.

If FebriDx sells well, and we can confirm ongoing 'royalties' PA AND add a good contract from the US Government via BARDA then all bets are off IMHO


We are almost certain to get the Royalties, so it's up to our sales force to get the orders rolling in.

The BARDA contract is the big one - a big repeating order from them and away we go.


Unfortunately we are incredible vulnerable to a takeover, which sadly I think may happen as soon as there is a sniff of a big BARDA contract.